In human cells, seven different 14-3-3 proteins regulate diverse cellular processes by binding to proteins with numerous functions (Yaffe, 2002) . In addition to regulation of 14-3-3 protein/ligand interactions by phosphorylation, the activity of 14-3-3 isoforms is controlled at the transcriptional level: for example, in epithelial cells, the expression of 14-3-3s is directly induced by p53 after DNA damage (Hermeking et al., 1997) . Elevated levels of 14-3-3s enforce a G 2 /M cell cycle arrest by sequestering Cdc2/cyclin B1 complexes in the cytoplasm (Hermeking et al., 1997; Chan et al., 1999) and are required for a stable G 2 /M arrest after DNA damage (Chan et al., 1999) . Furthermore, 14-3-3s binds to Cdk2 and Cdk4, suggesting that 14-3-3s may also affect G 1 /S-progression (Laronga et al., 2000) . In primary human keratinocytes, inactivation of 14-3-3s results in immortalization (Dellambra et al., 2000) . Taken together, these experimental observations suggest that inactivation of 14-3-3s may contribute to tumour formation. Consistent with this assumption, the 14-3-3s gene was identified as a direct target for epigenetic silencing via methylation of CpG-residues in 75% of 82 (91%) primary breast carcinomas analysed (Ferguson et al., 2000) .
Although a number of in vitro studies suggest that 14-3-3s acts on the cell cycle (Hermeking et al., 1997; Chan et al., 1999; Laronga et al., 2000) ; it is unclear at which sites 14-3-3s is expressed and which functions it mediates in vivo. In order to evaluate the potential requirement of 14-3-3s downregulation for hyperproliferation of keratinocytes, we examined the expression of 14-3-3s protein in several benign and neoplastic skin diseases that show epidermal hyperproliferation of keratinocytes, using an affinity-purified polyclonal antibody specific for 14-3-3s ( Figure 1 ): unexpectedly, in actinic keratoses (Figure 1a ), genital warts (condylomata acuminata; Figure 1b ), psoriasis ( Figure 1c ) and cutaneous squamous cell carcinoma (SCC; Figure 1d ) the level of 14-3-3s expression was equal to that of normal epidermis (Figure 1e , arrow) in all cases analysed (Table 1 ). These results demonstrate that downregulation of 14-3-3s protein is not a general requirement for hyperproliferation of keratinocytes. They further suggest that 14-3-3s may have additional functions that contribute to the expansion of keratinocytes. One function of 14-3-3s could be the prevention of apoptosis by cytoplasmic sequestration of the proapoptotic factor BAX, which has been observed in colorectal cancer cells (Samuel et al., 2001) . Keratinocytes within the hair follicles and the germinative portion of sebaceous glands stained strongly positive for 14-3-3s (Figure 1g, l) .
However, 14-3-3s protein levels were markedly downregulated in basal cell carcinoma (BCC; Figure  1e -k). The examples shown in Figure 1e -k are derived from five different BCC patients. As shown in Figure 1j and k (higher magnification of the BCC section shown in Figure 1i ), the basal cells of the epidermis express 14-3-3s protein. Towards the outer layers of the epidermis, the level of the 14-3-3s expression increased. Only a few keratinocytes within the tumour nests stained positive for 14-3-3s, particularly in portions of the tumour with a more morphoeic (Figure 1h ) or squamous differentiation pattern, where expression of 14-3-3s was found around cysts ( Figure 1f ). In total, 41 BCC were analysed for expression of 14-3-3s: 29 (70.7%) showed no or strongly reduced expression of 14-3-3s protein (Table 2) .
We then asked which molecular alterations could be responsible for the loss of 14-3-3s expression in BCC.
Figure 1 14-3-3s protein expression in hyperproliferative diseases of human skin. Paraffin-embedded samples (3 mm sections) of actinic keratosis (a), genital condyloma (b), psoriasis (c), SCC (d) and five different BCCs (e-i) were stained with an affinity-purified, polyclonal antibody specific for 14-3-3s (red). Higher magnifications of the tissue section shown in (i) are provided in (j) and (k). Nuclei (blue) were counterstained with haematoxylin (Ep: epidermis; Hf: hair follicle; SCC: squamous cell carcinoma; Sg: sebaceous gland). The specificity of the employed antibody (described in Chan et al., 1999) was verified using sections of paraffin-embedded 14-3-3s wt ( þ / þ ) and knockout (À/À) colon cancer cells (data not shown). Staining was performed on a Techmate plus 500 immunostainer (DAKO, Copenhagen, Denmark) with the APAAP-Kit (DAKO) and counterstaining with haematoxylin Loss of 14-3-3r expression in BCC D Lodygin et al 14-3-3s 14-3-3s 14-3-3s p16 p63 Patient no.
Keratinocytes representing BCC, adjacent normal epidermis or distant, normal epidermis derived from 41 patients (coded no. 1-41) were analysed as described in Figures 1-3 . Parallel sections were stained with a 14-3-3s-specific antiserum (third column). '+': staining similar to normal epidermal keratinocytes; 'À/+': staining significantly reduced; 'À': no staining (IHC ¼ immunohistochemical analysis). Results obtained by MSP are represented by '+/+': (positive for methylated (M) and nonmethylated (U) alleles) or 'À/+': (negative for methylated and positive for nonmethylated alleles). p63 protein expression was analysed in parallel sections obtained from BCC. Positive, nuclear p63 staining is indicated as '+' in the right column. Fields with no entries correspond to cases that were not analysed. Loss of 14-3-3r expression in BCC D Lodygin et al
Recently, the p53 homolog p63 was found to be a specific marker for keratinocyte stem cells (Pellegrini et al., 2001) . The loss of 14-3-3s expression detected in BCC could therefore be due to expression of a dominant-negative splice variant of p63 (DNp63/ CUSP), which is expressed in the epidermal stem cell compartment, from which BCC is presumably derived, and may affect 14-3-3s expression via the p53-binding sites in the 14-3-3s promoter (Westfall et al., 2003) . Therefore, we analysed the expression of p63. Indeed, all 20 BCC analysed were positive for nuclear p63 protein (Figure 2a ; Tables 1 and 2 ). However, seven of the 20 BCC tested showed expression of both 14-3-3s and p63 protein (Table 2) . Furthermore, cells representing actinic keratoses (6/6) and SCC (6/6), which expressed high levels of 14-3-3s, were also positive for p63 (Figure 2c , e; Table 1 ). Therefore, no direct correlation between the absence of 14-3-3s expression and presence of p63 exists inBCC. Since 14-3-3s is silenced by CpG-island methylation in breast carcinomas (Ferguson et al., 2000) , we evaluated the methylation status of 14-3-3s in BCC by methylation-specific PCR (MSP). The specificity of the employed PCR primers (Figure 3a ) and the conditions for MSP were confirmed by analysis of the 14-3-3s methylation status in the breast cancer cell line MDA-MB-435S, in which 14-3-3s undergoes complete methylation (Ferguson et al., 2000) . As shown in Figure 3b , only a 105 bp (base pair) PCR product specific for methylated CpG-residues but no product representing a nonmethylated 14-3-3s allele was detected in MDA-MB-435S cells. Furthermore, the colorectal cancer cell line HCT116, which expresses 14-3-3s, did not show CpG-methylation, but was positive for the 107 bp product representing a nonmethylated 14-3-3s allele (Figure 3b ). Laser-capture microdissection was employed to isolate BCC tissue samples from paraffin sections obtained from 41 patients. This approach allowed the precise separation of BCC from mesenchymal stroma, in which 14-3-3s is silenced by CpG-methylation (Umbricht et al., 2001) . Consistent with CpG-methylation of 14-3-3s in stromal fibroblasts, we could detect methylation of 14-3-3s in normal human diploid fibroblasts (HDF) passaged in vitro (Figure 3b ). MSP with genomic DNA extracted from BCC revealed that 14-3-3s promoter methylation was present in 28 of 41 (68.3%) of the analysed BCC samples ( Figure 3c , Table 2 ). All samples also demonstrated a signal specific for the nonmethylated allele of 14-3-3s ( Figure 3c , Table 2 ). The concomitant presence of nonmethylated and methylated 14-3-3s promoter sequences has been observed previously in breast cancer lesions (Umbricht et al., 2001) . Immunohistochemical analysis of sections parallel to the sections analysed by MSP confirmed strong suppression or absence of 14-3-3s protein expression in keratinocytes representing BCC in 22 of the 28 (78.6%) cases which displayed CpG-methylation of 14-3-3s ( Table 2 ). The expression of 14-3-3s in six cases with CpGmethylation of 14-3-3s may be driven by the nonmethylated allele. Surprisingly, keratinocytes derived from normal epidermis adjacent to the BCC lesions also showed methylation of CpG-residues at the 14-3-3s locus in seven of 17 (41.2%) cases analysed (Table 2, column 4; Figure 3d -e). The CpG-methylation detected in keratinocytes from adjacent, normal epidermis did not lead to a reduced expression of 14-3-3s protein as detected by immunohistochemistry (data not shown). However, epidermis isolated from distant sites adjacent to naevocytic naevi from the identical patient was negative for CpG-methylation ( Figure 3f ; Table 2 , column 5). Recent studies showed that 14-3-3s is also methylated in epithelial cells derived from histologically normal tissue surrounding breast carcinomas (Umbricht et al., 2001) or hepatocellular carcinoma (Iwata et al., 2000) . However, methylation of 14-3-3s was never detected in breast epithelial tissue derived from cancer-free donors (Umbricht et al., 2001) . Therefore, it has been suggested that CpG-methylation of 14-3-3s represents a precursor lesion, which precedes any morphological change in tissue architecture. Several other genes, which are inactivated during tumour development, show CpGmethylation in tissue adjacent to tumour tissue (Ivanova et al., 2002; Li et al., 2002; Tokugawa et al., 2002) . CpG-methylation of 14-3-3s in the normal epidermis may indicate the presence BCC precursor cells. However, it will be necessary to further characterize the relation of these neighbouring cells to BCCs to conclude that 14-3-3s methylation is a marker for BCC precursor cells.
In primary human keratinocytes, inactivation of 14-3-3s results in evasion from senescence (Dellambra et al., 2000) . In order to determine whether other genes implicated in the induction of senescence are silenced by CpG-methylation in BCC, the methylation status of p16 INK4A was analysed by MSP. In 17 cases of BCC with methylated 14-3-3s, no CpG-methylation of p16 INK4A was detected (Table 2 , column 6 and Figure 3g ). Only in one out of nine BCC harbouring exclusively nonmethylated 14-3-3s alleles, the p16 INK4A promoter was found to be methylated (Table 2 , column 6). Several studies have shown that p16 INK4A is not a target for inactivation by point-mutations or deletions in BCC (Saridaki et al., 2000 and references therein) . Taken together, these results suggest that silencing of 14-3-3s may be the preferred route for evasion of senescence in BCC.
Here we have shown that downregulation of the antiproliferative 14-3-3s protein is a characteristic feature of BCC, which is associated with CpG-methylation of the 14-3-3s promoter. In a fraction of BCC, 14-3-3s expression was lost in the absence of CpGmethylation. This could be due to mutational inactivation of 14-3-3s. However, although the 14-3-3s gene is localized on chromosome 1p35, a region frequently deleted in cancer, mutational inactivation of 14-3-3s has not been observed yet. In colorectal cancer, analysis of 40 tumours with LOH at the 14-3-3s locus revealed no mutations in the remaining 14-3-3s allele (Hermeking et al., unpublished results) . Similarly, rare cases of LOH at the 14-3-3s locus have been observed in oral squamous cell carcinomas (Gasco et al., 2002) . However, the remaining 14-3-3s allele was not mutated. Recently, an alternative mechanism for loss of 14-3-3s protein has been identified: the ubiquitin E3-ligase EFP targets the 14-3-3s protein for proteasomal degradation (Urano et al., 2002) . Therefore, upregulation of EFP could potentially account for the loss of 14-3-3s protein in those cases of BCC where no CpG-methylation is detected.
Until now it has been impossible to cultivate BCC cells in vitro. Therefore, the functional consequences of INK4A alleles. For the analyses shown in (c)-(g) paraffin-embedded 10 mm sections were laser-microdissected using a MicroBeam-system (PALM, Bernried, Germany). MSP was performed as described previously (Herman et al., 1996; Ferguson et al., 2000) . PCR products were resolved on 8% polyacrylamide gels and stained with ethidium bromide.
Loss of 14-3-3r expression in BCC D Lodygin et al 14-3-3s downregulation were not amenable to functional analysis in this study. In several tumour cell lines, demethylation of 14-3-3s by 5-aza-2 0 -deoxycytidine leads to re-expression of the 14-3-3s mRNA (e.g. Ferguson et al., 2000) , showing that CpG-methylation is causally involved in silencing of 14-3-3s. In breast cancer cells, silencing of 14-3-3s is associated with a defect in the G 2 /M checkpoint (Ferguson et al., 2000) . It is likely that the CpG-methylation of 14-3-3s detected here in BCC has similar functional consequences.
With 750 000 new cases each year, BCC is the most common malignancy in the US (Miller, 1991) . BCCs rarely metastasize, but may lead to significant morbidity because of local tissue destruction (Schubert and Muller, 1997) . Our finding, that 14-3-3s expression is lost in the majority of BCC, provides an opportunity to devise selective therapeutic means, since loss of 14-3-3s sensitizes epithelial cells to DNA-damaging agents (Chan et al., 1999 : Samuel et al., 2001 and may explain the effectiveness of radiotherapy for treatment of BCC.
Abbreviations BCC, basal cell carcinoma; bp, base pair; Cdk, Cyclindependent kinase; HDF, human diploid fibroblasts; MSP, methylation-specific PCR; SCC, squamous cell carcinoma.
